As con­tro­ver­sy over child­hood deaths sim­mers in the Philip­pines, Sanofi balks at a Deng­vax­ia re­im­burse­ment

Sanofi is in the mid­dle of a heat­ed con­tro­ver­sy in the Philip­pines that shows no signs of dy­ing out any­time soon.

Over the last few days the phar­ma gi­ant has had to re­ject calls for re­im­burs­ing the gov­ern­ment for the cost of hun­dreds of thou­sands of dos­es of Deng­vax­ia. And pub­lic health of­fi­cials raised a ruckus by point­ing to sev­er­al deaths among chil­dren which they say could have been trig­gered by the vac­cine. In the mean­time there are signs that the pan­ic over Deng­vax­ia has raised fears about all such jabs, lead­ing to a sharp drop in bad­ly need­ed vac­ci­na­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.